Telomerase reverse transcriptase immunohistochemical expression is sensitive but not specific for TERT gene amplification in acral melanoma

BACKGROUND TERT gene amplification (TGA) is a mechanism of telomerase reverse transcriptase (TERT) upregulation frequently utilized by acral melanomas (AMs). Currently, the utility of TERT immunohistochemistry (IHC) to predict TGA status in AMs is poorly documented. METHODS AMs (26 primary and 3 metastatic) and non-acral cutaneous melanomas (6 primary) were subjected to immunohistochemical analysis using anti-TERT antibody to demonstrate protein expression and fluorescence in situ hybridization (FISH) to assess genomic copy number alteration. The relationship between TERT immunoreactivity and TGA confirmed by FISH was assessed using logistic regression. RESULTS TERT expression was seen in 50% (13/26) of primary and 100% (3/3) of metastatic AMs and 50% (3/6) of primary non-acral cutaneous melanomas. TGA was found in 15% (4/26) and 67% (2/3) of primary and metastatic AMs and 17% (1/6) of non-acral cutaneous melanomas. The intensity of TERT immunoreactivity correlated with TGA (p = 0.04) and a higher TERT copy number-to-control ratio in AMs, with a correlation coefficient of 0.41 (p = 0.03). The sensitivity and specificity of TERT immunoreactivity for predicting TGA in AMs were 100% and 57%, with corresponding positive and negative predictive values of 38% and 100%, respectively. CONCLUSIONS The clinical utility of TERT IHC to predict TGA status in AMs appears to be limited given its low specificity and positive predictive value.

[1]  U. Tabori,et al.  DNA methylation of the TERT promoter and its impact on human cancer. , 2020, Current opinion in genetics & development.

[2]  P. Kwok,et al.  Targeted genomic profiling of acral melanoma. , 2019, Journal of the National Cancer Institute.

[3]  L. Akslen,et al.  Prognostic impact and concordance of TERT promoter mutation and protein expression in matched primary and metastatic cutaneous melanoma , 2017, British Journal of Cancer.

[4]  Xin Hu,et al.  Systematic analysis of telomere length and somatic alterations in 31 cancer types , 2017, Nature Genetics.

[5]  J. Malvehy,et al.  TERT gene amplification is associated with poor outcome in acral lentiginous melanoma. , 2014, Journal of the American Academy of Dermatology.

[6]  D. Schadendorf,et al.  TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. , 2014, Journal of the National Cancer Institute.

[7]  M. Honavar,et al.  TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation. , 2014, The Journal of investigative dermatology.

[8]  Y. Jeng,et al.  TERT promoter mutation is uncommon in acral lentiginous melanoma , 2014, Journal of cutaneous pathology.

[9]  J. Malvehy,et al.  TERT and AURKA gene copy number gains enhance the detection of acral lentiginous melanomas by fluorescence in situ hybridization. , 2014, The Journal of molecular diagnostics : JMD.

[10]  J. Becker,et al.  Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma , 2014, Nature Communications.

[11]  Miguel Melo,et al.  Frequency of TERT promoter mutations in human cancers , 2013, Nature Communications.

[12]  J. Malvehy,et al.  Genetic alterations in RAS‐regulated pathway in acral lentiginous melanoma , 2013, Experimental dermatology.

[13]  K. Rudolph,et al.  The Role of Telomeres in Stem Cells and Cancer , 2013, Cell.

[14]  M. Llavador Ros,et al.  Telomerase Expression in a Series of Melanocytic Neoplasms. , 2018, Actas dermo-sifiliograficas.

[15]  H. Tsao,et al.  Telomerase reverse transcriptase (TERT) promoter mutations in Korean melanoma patients. , 2017, American journal of cancer research.